Future Prescriber Wiley Online Library : Future Prescriberhttp://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2F%28ISSN%291931-2261John Wiley & Sons, IncenCopyright © John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ1468-98711931-22612012-12-01T00:00:00-05:00December 2012133523Dexmedetomidine: a unique clinical profile in ICU sedationhttp://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Ffps.96Dexmedetomidine: a unique clinical profile in ICU sedationSteve Chaplin2013-01-16T10:50:54.187711-05:00doi:10.1002/fps.96John Wiley & Sons, Inc.10.1002/fps.96http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Ffps.96Drug Profile59Abstract

Dexmedetomidine is a sedating agent with a pharmacological and therapeutic profile that is unlike those of the most commonly used sedative agents (midazolam and propofol). In this article, we provide an over view of dexmedetomidine in terms of its pharmacokinetics and pharmacodynamics, and describe its place in the management of patients in intensive care. Copyright © 2013 John Wiley & Sons, Ltd.

]]> Dexmedetomidine is a sedating agent with a pharmacological and therapeutic profile that is unlike those of the most commonly used sedative agents (midazolam and propofol). In this article, we provide an over view of dexmedetomidine in terms of its pharmacokinetics and pharmacodynamics, and describe its place in the management of patients in intensive care. Copyright © 2013 John Wiley & Sons, Ltd. Mirabegron use in the treatment of overactive bladder symptomshttp://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Ffps.97Mirabegron use in the treatment of overactive bladder symptomsG Alessandro Digesu, Michelle Gore, Vik Khullar2013-01-16T10:50:54.187711-05:00doi:10.1002/fps.97John Wiley & Sons, Inc.10.1002/fps.97http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Ffps.97Drug Profile1013Abstract

Beta-3 adrenoreceptors have been proposed as a target in the treatment of OAB due to their role in the mediation of bladder smooth muscle relaxation. Mirabegron is an oral medication that selectively targets beta-3 adrenoreceptors and has been shown to reduce rhythmic abnormal detrusor contractions in animal models. In this Drug profile the authors present the clinical data relating to its efficacy and adverse effects and discuss its potential place in the treatment of OAB. Copyright © 2013 John Wiley & Sons, Ltd.

]]> Beta-3 adrenoreceptors have been proposed as a target in the treatment of OAB due to their role in the mediation of bladder smooth muscle relaxation. Mirabegron is an oral medication that selectively targets beta-3 adrenoreceptors and has been shown to reduce rhythmic abnormal detrusor contractions in animal models. In this Drug profile the authors present the clinical data relating to its efficacy and adverse effects and discuss its potential place in the treatment of OAB. Copyright © 2013 John Wiley & Sons, Ltd. Linaclotide for irritable bowel syndrome with constipationhttp://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Ffps.98Linaclotide for irritable bowel syndrome with constipationSteve Chaplin2013-01-16T10:50:54.187711-05:00doi:10.1002/fps.98John Wiley & Sons, Inc.10.1002/fps.98http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Ffps.98Drug Profile1416Abstract

Linaclotide is a guanylate cyclase agonist that promotes increased stool water content, which increases bowel movement frequency. It has recently received a positive opinion from the CHMP for the treatment of constipation-predominant IBS. In this Drug profile Steve Chaplin presents the clinical data relating to its efficacy and adverse events. Copyright © 2013 John Wiley & Sons, Ltd.

]]> Linaclotide is a guanylate cyclase agonist that promotes increased stool water content, which increases bowel movement frequency. It has recently received a positive opinion from the CHMP for the treatment of constipation-predominant IBS. In this Drug profile Steve Chaplin presents the clinical data relating to its efficacy and adverse events. Copyright © 2013 John Wiley & Sons, Ltd. Ingenol mebutate: a novel topical agent for actinic keratosishttp://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Ffps.99Ingenol mebutate: a novel topical agent for actinic keratosisColin A Morton2013-01-16T10:50:54.187711-05:00doi:10.1002/fps.99John Wiley & Sons, Inc.10.1002/fps.99http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Ffps.99Drug Profile1719Abstract

Ingenol mebutate is a once-daily topical treatment for actinic keratosis (AK) that is applied for only two or three days depending on body site. It has recently been approved by the FDA for the treatment of AK on the face, scalp, trunk and extremities and recommended for approval by the CHMP in September 2012. In this drug profile, the author reviews its mode of action, efficacy and tolerability and comments on the drug's likely place in practice. Copyright © 2013 John Wiley & Sons, Ltd.

]]> Ingenol mebutate is a once-daily topical treatment for actinic keratosis (AK) that is applied for only two or three days depending on body site. It has recently been approved by the FDA for the treatment of AK on the face, scalp, trunk and extremities and recommended for approval by the CHMP in September 2012. In this drug profile, the author reviews its mode of action, efficacy and tolerability and comments on the drug's likely place in practice. Copyright © 2013 John Wiley & Sons, Ltd. Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosishttp://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Ffps.100Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosisAdam Mead2013-01-16T10:50:54.187711-05:00doi:10.1002/fps.100John Wiley & Sons, Inc.10.1002/fps.100http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Ffps.100Drug Profile2023Abstract

Ruxolitinib is an orally administered JAK2 inhibitor for the treatment of disease-related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley & Sons, Ltd.

]]> Ruxolitinib is an orally administered JAK2 inhibitor for the treatment of disease-related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley & Sons, Ltd.